Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28131538 | 0.91 | LPAR3 (0.57) | CYP3A4LPAR3LPAR1LPAR2TRPM8 | |
| SCHEMBL10831955 | 0.84 | CYP3A4 (0.56) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL7804487 | 0.82 | CYP3A4 (0.54) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL3291222 | 0.82 | CYP3A4 (0.54) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL28846287 | 0.80 | LPAR3 (0.50) | CYP3A4LPAR3LPAR1LPAR2TRPM8 | |
| SCHEMBL4449162 | 0.79 | CYP3A4 (0.56) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL19595699 | 0.79 | CYP3A4 (0.56) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL13597922 | 0.79 | CYP3A4 (0.56) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL13618686 | 0.79 | CYP3A4 (0.56) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL2969240 | 0.79 | CYP3A4 (0.50) | CYP3A4LPAR3LPAR1LPAR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9732029-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9725402-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9663543-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20140336137-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | CARDIOXYL PHARMACEUTICALS, INC. | 2014-11-13 | — | — | US | disclosed |
| US-8791134-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130045951-A1 | Novel Nitroso Compounds as Nitroxyl Donors and Methods of Use Thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-8318705-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20090281062-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | EVOTEC LTD. (GB) | 2009-11-12 | — | — | US | disclosed |
| US-7582605-B2 | Phosphorus-containing hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080039375-A1 | Phosphorus-containing hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | CYP3A4 4376/4885LPAR3 1414/4885LPAR1 1407/4885 |
| US-20140336137-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | NOXO1, TNNI3, HAO2 | CYP3A4 1853/4885LPAR3 2024/4885LPAR1 1900/4885 |
| US-20090281062-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | NOXO1, TNNI3, HAO2 | CYP3A4 1853/4885LPAR3 2024/4885LPAR1 1900/4885 |
| US-20130045951-A1 | Novel Nitroso Compounds as Nitroxyl Donors and Methods of Use Thereof | NOXO1, TNNI3, HAO2 | CYP3A4 1853/4885LPAR3 2024/4885LPAR1 1900/4885 |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C1QBP | CYP3A4 4692/4885LPAR3 383/4885LPAR1 402/4885 |
| US-20080039375-A1 | Phosphorus-containing hepatitis C serine protease inhibitors | PRSS1, PPP4C, G6PC1 | CYP3A4 413/4885LPAR3 1657/4885LPAR1 1627/4885 |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C1QBP | CYP3A4 4692/4885LPAR3 383/4885LPAR1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.